Stay updated with the latest sinusitis news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on sinusitis topics.
Hyderabad: CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, on Monday said it has reported positive top-line Phase 3 results for BP11, its investigational biosimilar to Xolair, or omalizumab.CuraTeQ said the study met all primary endpoints in patients with chronic spontaneous urticaria receiving the 300 mg dose, demonstrating high comparability with the reference product. The company said it plans to use the results to support regulatory submissions for chronic spontaneous urtic ...Read More >
Hyderabad, April 6 (RAHNUMA): CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has announced positive top-line results from its Phase 3 trial of BP11, an investigational biosimilar to Omalizumab (marketed as Xolair). The study met all primary endpoints, demonstrating strong comparability with the reference drug in treating chronic spontaneous urticaria (CSU) at a 300 mg dose. Conducted across 608 patients at nearly 80 sites in Europe and India, the trial showed precise equivalence in itch s ...Read More >
Lucknow: This Diwali, residents of the city were exposed to decibel levels equivalent to noise made by a food blender switched on for hours. On Diwali night, noise levels exceeded standards at all sites, with highest value of 89.3 decibels (dB(A)) at Vikasnagar and the lowest of 75.8 dB (A) at Chowk on Diwali night, stated Indian Institute of Toxicology Research's air and noise quality assessment report for Lucknow during Diwali 2025, released on Thursday.Compared to the day before Diwali, noise ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.